MX2018012619A - Derivados de bisfenol y su uso como moduladores de la actividad del receptor de androgeno. - Google Patents
Derivados de bisfenol y su uso como moduladores de la actividad del receptor de androgeno.Info
- Publication number
- MX2018012619A MX2018012619A MX2018012619A MX2018012619A MX2018012619A MX 2018012619 A MX2018012619 A MX 2018012619A MX 2018012619 A MX2018012619 A MX 2018012619A MX 2018012619 A MX2018012619 A MX 2018012619A MX 2018012619 A MX2018012619 A MX 2018012619A
- Authority
- MX
- Mexico
- Prior art keywords
- androgen receptor
- receptor activity
- activity modulators
- bisphenol derivatives
- compounds
- Prior art date
Links
- 102000001307 androgen receptors Human genes 0.000 title abstract 2
- 108010080146 androgen receptors Proteins 0.000 title abstract 2
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical class C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporcionan los compuestos que tienen una estructura de la Fórmula I: (ver Fórmula) o una sal, tautómero o estereoisómero farmacéuticamente aceptable de estos, donde R1, R2, R3, R11a, R11b, R11c, R11d, y X, son tal como se definen en la. También se proporcionan usos de tales compuestos para modular la actividad del receptor de andrógeno, diagnósticos por imaginología de cáncer y terapéutica, y métodos para el tratamiento de sujetos que lo necesitan, que incluye el cáncer de próstata.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662323196P | 2016-04-15 | 2016-04-15 | |
PCT/CA2017/000083 WO2017177307A1 (en) | 2016-04-15 | 2017-04-18 | Bisphenol derivatives and their use as androgen receptor activity modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018012619A true MX2018012619A (es) | 2019-06-24 |
Family
ID=60039402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012619A MX2018012619A (es) | 2016-04-15 | 2017-04-18 | Derivados de bisfenol y su uso como moduladores de la actividad del receptor de androgeno. |
Country Status (14)
Country | Link |
---|---|
US (3) | US20170298033A1 (es) |
EP (1) | EP3442942B1 (es) |
JP (2) | JP7142577B2 (es) |
KR (1) | KR102409651B1 (es) |
CN (1) | CN109311807B (es) |
AU (1) | AU2017250025B2 (es) |
BR (1) | BR112018071183B1 (es) |
CA (1) | CA3021008A1 (es) |
ES (1) | ES2969445T3 (es) |
IL (1) | IL262338B (es) |
MX (1) | MX2018012619A (es) |
NZ (1) | NZ748200A (es) |
RU (1) | RU2767257C2 (es) |
WO (1) | WO2017177307A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE057962T2 (hu) | 2015-01-13 | 2022-06-28 | British Columbia Cancer Agency Branch | Heterociklusos vegyületek rák képalkotására és kezelésére és eljárás ezek alkalamzására |
US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
WO2018045450A1 (en) * | 2016-09-09 | 2018-03-15 | British Columbia Cancer Agency Branch | Bisphenol a compounds and methods for treating drug-resistant androgen receptor mediated cancers |
US11485713B2 (en) | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
PE20211543A1 (es) * | 2018-10-18 | 2021-08-16 | Essa Pharma Inc | Moduladores del receptor de androgenos y metodos para su uso |
CN114502539A (zh) * | 2019-03-28 | 2022-05-13 | 埃萨制药股份有限公司 | 包含雄激素受体的抑制剂的药物组合物和组合及其用途 |
WO2020198712A1 (en) * | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
CN118085015A (zh) * | 2019-09-06 | 2024-05-28 | 江西济民可信集团有限公司 | 作为蛋白降解剂的并环类化合物及其制备方法和用途 |
JP2023522040A (ja) | 2020-04-17 | 2023-05-26 | エッサ ファーマ,インコーポレイテッド | N末端ドメインアンドロゲン受容体阻害剤の固体形態およびその使用 |
CN113648418B (zh) * | 2021-05-08 | 2022-08-05 | 南方医科大学 | Apelin-APJ抑制剂在制备治疗血睾屏障损伤药物中的应用 |
KR20220157089A (ko) * | 2021-05-20 | 2022-11-29 | 연세대학교 산학협력단 | 암의 예방, 개선 또는 치료용 조성물 |
KR20220157096A (ko) * | 2021-05-20 | 2022-11-29 | 연세대학교 산학협력단 | 암의 예방, 개선 또는 치료용 조성물 |
WO2023046283A1 (en) | 2021-09-22 | 2023-03-30 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Compounds and their use in a method for modulating ar (androgen receptor) transcriptional activity |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2571217A (en) | 1951-10-16 | Horace s | ||
US2890189A (en) | 1954-06-14 | 1959-06-09 | Johnson & Son Inc S C | Alkali soluble resins and compositions containing the same |
US3074974A (en) * | 1957-12-06 | 1963-01-22 | Monsanto Chemicals | Method for the preparation of diglycidyl ether of tetrachlorobisphenol-a |
US3162615A (en) | 1961-01-03 | 1964-12-22 | Dow Chemical Co | Polyesters from cyclic polyhaloalkane polyols and unsaturated dicarboxylic acids |
FR1389005A (fr) | 1963-01-09 | 1965-02-12 | Bayer Ag | Procédé perfectionné pour durcir des polyépoxydes |
SU638596A1 (ru) | 1975-09-01 | 1978-12-25 | Государственный Научно-Исследовательский И Проектный Институт Полимерных Клеев Им. Э.Л.Тер-Газаряна | Хлоргидриднное производное диаллилизоциануровой кислоты в качестве пластификатора поливинилацетатной эмульсии |
US4284574A (en) | 1979-06-15 | 1981-08-18 | Ciba-Geigy Corporation | Diglycidyl ethers of di-secondary alcohols, their preparation, and curable compositions containing them |
SU929630A1 (ru) * | 1980-02-06 | 1982-05-23 | Научно-Исследовательский Институт Биологии При Иркутском Государственном Университете Им.А.А.Жданова | Способ получени ди-или триоксидифенил-сульфонов |
US4369298A (en) | 1980-05-27 | 1983-01-18 | Tokuyama Soda Kabushiki Kaisha | Novel cured resin, process for production thereof, and lens composed of said resin from bis(alkyleneoxyphenyl)-diacrylate, bis(alkyleneoxyphenyl)diallyl ether, bis(alkyleneoxyphenyl)diallyl carbonate monomers |
DE3170223D1 (en) | 1981-01-13 | 1985-06-05 | Teijin Ltd | Ion-permeable composite membrane and its use in selective separation |
IN169231B (es) * | 1984-03-15 | 1991-09-14 | Ciba Geigy Ag | |
PL141793B1 (en) | 1984-10-08 | 1987-08-31 | Politechnika Warszawska | Method of obtaining bisphenolic resins |
US5753730A (en) | 1986-12-15 | 1998-05-19 | Mitsui Toatsu Chemicals, Inc. | Plastic lenses having a high-refractive index, process for the preparation thereof and casting polymerization process for preparing sulfur-containing urethane resin lens and lens prepared thereby |
JPH0832844B2 (ja) | 1987-02-09 | 1996-03-29 | パイロツトインキ株式会社 | 筆記板用不透明性インキ |
US4904760A (en) | 1987-04-27 | 1990-02-27 | Mitsubishi Gas Chemical Co., Inc. | Thermosetting resin composition from cyanate ester and non-branched aromatic compound |
WO1988009782A1 (en) | 1987-06-01 | 1988-12-15 | The Dow Chemical Company | Process for making propargyl ethers of hydroxyaromatic compounds |
US5155196A (en) | 1987-06-01 | 1992-10-13 | The Dow Chemical Company | Polymer resulting from the cure of a preformed chromene-containing mixture |
JP2572020B2 (ja) * | 1987-06-19 | 1997-01-16 | 竹本油脂株式会社 | 熱硬化性樹脂用難燃剤 |
DE3821585A1 (de) | 1987-09-13 | 1989-03-23 | Hoechst Ag | Positiv arbeitendes strahlungsempfindliches gemisch und daraus hergestelltes strahlungsempfindliches aufzeichnungsmaterial fuer hochenergetische strahlung |
US4855184A (en) | 1988-02-02 | 1989-08-08 | Minnesota Mining And Manufacturing Company | Radiation-curable protective coating composition |
DE3939760A1 (de) | 1989-12-01 | 1991-06-06 | Bayer Ag | Verfahren zur lackierung von kunststoffen, lackierte kunststoffe und die verwendung von hierzu geeigneten haftvermittlern |
EP0515128A1 (en) | 1991-05-23 | 1992-11-25 | Konica Corporation | Silver halide color photographic light-sensitive material |
JPH0649473A (ja) | 1992-08-04 | 1994-02-22 | Asahi Chem Ind Co Ltd | 冷媒組成物 |
DE4323512A1 (de) | 1992-09-01 | 1994-04-28 | Agfa Gevaert Ag | Fotografisches Aufzeichnungsmaterial |
JPH07117349A (ja) | 1993-10-27 | 1995-05-09 | Asahi Denka Kogyo Kk | 感熱記録材料 |
CA2206422A1 (en) | 1994-11-29 | 1996-06-06 | Hoechst Marion Roussel, Inc. | Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis |
DE19526146A1 (de) | 1995-07-07 | 1997-01-09 | Schering Ag | Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
JPH09176240A (ja) | 1995-12-27 | 1997-07-08 | Mitsubishi Chem Corp | 光重合性組成物 |
JPH10133427A (ja) | 1996-11-05 | 1998-05-22 | Fuji Xerox Co Ltd | 静電潜像現像用キャリア、静電潜像現像剤及び画像形成方法 |
ZA98900B (en) | 1997-02-07 | 1998-08-03 | Shell Int Research | Process for the manufacture of epoxy compounds |
JPH10316803A (ja) | 1997-05-16 | 1998-12-02 | Teijin Chem Ltd | 難燃性樹脂組成物 |
IL125840A (en) | 1997-08-22 | 2002-12-01 | Teijin Chemicals Ltd | Bromine compound production method |
JPH11166087A (ja) | 1997-12-04 | 1999-06-22 | Teijin Chem Ltd | 難燃性樹脂組成物 |
AU4494399A (en) | 1998-06-30 | 2000-01-24 | University Of British Columbia, The | Inhibitors of androgen-independent activation of androgen receptor |
US6245117B1 (en) | 1998-08-07 | 2001-06-12 | Ipposha Oil Industries Co., Ltd. | Modifier of cellulose fibers and modification method of cellulose fibers |
US6218430B1 (en) | 1998-08-24 | 2001-04-17 | Ligand Pharmaceuticals Incorporated | Vitamin D3 mimics |
JP3795679B2 (ja) | 1998-09-01 | 2006-07-12 | 帝人化成株式会社 | 臭素化合物の製造方法 |
EP1222459A4 (en) | 1999-10-14 | 2003-01-22 | Bristol Myers Squibb Co | CRYSTALLOGRAPHIC STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN |
US6534621B2 (en) | 2000-05-18 | 2003-03-18 | Dow Global Technologies Inc. | Process for manufacturing a hydroxyester derivative intermediate and epoxy resins prepared therefrom |
US6472436B1 (en) | 2000-07-17 | 2002-10-29 | The Salk Institute For Biological Studies | Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production |
US6756400B2 (en) | 2000-08-31 | 2004-06-29 | Theravance, Inc. | Sodium channel modulators |
US6646102B2 (en) | 2001-07-05 | 2003-11-11 | Dow Global Technologies Inc. | Process for manufacturing an alpha-dihydroxy derivative and epoxy resins prepared therefrom |
US20030092724A1 (en) | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
WO2003074450A2 (en) | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
US7022870B2 (en) | 2002-06-17 | 2006-04-04 | University Of Tennessee Research Foundation | N-bridged selective androgen receptor modulators and methods of use thereof |
GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
WO2005051893A2 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
EP2581382A2 (en) | 2004-02-13 | 2013-04-17 | The University Of British Columbia | Radiolabeled compounds and compositions, their precursors and methods for their production |
JP2005325301A (ja) | 2004-05-17 | 2005-11-24 | Fuji Photo Film Co Ltd | セルロースアシレートドープ組成物、およびセルロースアシレートフィルム |
MX2007001993A (es) | 2004-08-18 | 2007-05-10 | Warner Lambert Co | Moduladores de androgenos. |
JP2006208607A (ja) | 2005-01-26 | 2006-08-10 | Fuji Photo Film Co Ltd | パターン形成材料、並びにパターン形成装置及び永久パターン形成方法 |
EP1861365B1 (en) | 2005-03-15 | 2009-07-01 | 4Sc Ag | N-sulphonylpyrroles and their use as histone deacetylase inhibitors |
JP4753601B2 (ja) | 2005-03-23 | 2011-08-24 | 旭化成イーマテリアルズ株式会社 | 感光性組成物 |
EP1717235A3 (en) | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
EP1792622A1 (en) | 2005-11-11 | 2007-06-06 | GPC Biotech AG | Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues |
SI1976828T1 (sl) | 2005-12-29 | 2017-07-31 | Celtaxsys, Inc. | Diaminski derivati kot inhibitorji levkotrien A4 hidrolaze |
PL2656841T3 (pl) | 2006-03-27 | 2017-01-31 | The Regents Of The University Of California | Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym |
JP2007290980A (ja) | 2006-04-21 | 2007-11-08 | Shin Etsu Chem Co Ltd | 含フッ素(メタ)アクリル酸エステル |
DE102006019044A1 (de) * | 2006-04-25 | 2007-10-31 | Merck Patent Gmbh | Antioxidantien |
TW200819421A (en) | 2006-10-31 | 2008-05-01 | Univ Nat Chunghsing | The method of synthesizing biphenol A, BPA having di-alkoxyl group by using polycarbonate or its waste |
WO2008101806A2 (en) | 2007-02-20 | 2008-08-28 | Basf Se | High refractive index monomers, compositions and uses thereof |
CN105012282A (zh) | 2008-07-02 | 2015-11-04 | 不列颠哥伦比亚癌症局分支机构 | 二缩水甘油醚衍生物治疗剂和它们的使用方法 |
AU2009279936A1 (en) | 2008-08-05 | 2010-02-11 | Banyu Pharmaceutical Co., Ltd. | Therapeutic compounds |
US20130109758A1 (en) | 2010-01-06 | 2013-05-02 | The University Of British Columbia | Bisphenol derivative therapeutics and methods for their use |
WO2011082487A1 (en) | 2010-01-06 | 2011-07-14 | British Columbia Cancer Agency Branch | Bisphenol derivatives and their use as androgen receptor activity modulators |
SG10201907588XA (en) | 2010-02-16 | 2019-09-27 | Aragon Pharmaceuticals Inc | Androgen Receptor Modulators And Uses Thereof |
EP2693875A4 (en) | 2011-04-08 | 2014-10-22 | British Columbia Cancer Agency | BISPHENOL COMPOUNDS AND METHODS OF USE |
WO2012145328A1 (en) | 2011-04-18 | 2012-10-26 | The University Of British Columbia | Dibenzylphenyl compounds and methods for their use |
WO2012145330A1 (en) | 2011-04-18 | 2012-10-26 | The University Of British Columbia | Fluorene-9-bisphenol compounds and methods for their use |
EP2744773B1 (en) | 2011-08-19 | 2016-11-02 | British Columbia Cancer Agency Branch | Fluorinated bisphenol ether compounds and methods for their use |
WO2013028791A1 (en) | 2011-08-22 | 2013-02-28 | British Columbia Cancer Agency Branch | 18f compounds for cancer imaging and methods for their use |
US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
EP3733170A1 (en) | 2012-07-13 | 2020-11-04 | Oncternal Therapeutics, Inc. | A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms) |
JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
WO2014179867A1 (en) | 2013-05-10 | 2014-11-13 | British Columbia Cancer Agency Branch | Ester derivatives of androgen receptor modulators and methods for their use |
CN103342892A (zh) | 2013-06-06 | 2013-10-09 | 西安交通大学 | 一种双马来酰亚胺树脂的增韧改性剂及其制备方法 |
US20150010469A1 (en) * | 2013-07-03 | 2015-01-08 | British Columbia Cancer Agency Branch | Bisphenol ether compounds with novel bridging groups and methods for their use |
AU2014317753A1 (en) | 2013-09-09 | 2016-04-07 | British Columbia Cancer Agency Branch | Halogenated compounds for cancer imaging and treatment and methods for their use |
TW201600499A (zh) | 2014-05-15 | 2016-01-01 | 巴斯夫歐洲公司 | 用於製備石墨烯奈米帶的鄰三聯苯 |
WO2016058082A1 (en) | 2014-10-14 | 2016-04-21 | British Columbia Cancer Agency Branch | 18f compounds for cancer imaging and methods for their use |
WO2016058080A1 (en) | 2014-10-14 | 2016-04-21 | British Columbia Cancer Agency Branch | Fluoro-chloro bisphenol ether compounds and methods for their use |
HUE057962T2 (hu) | 2015-01-13 | 2022-06-28 | British Columbia Cancer Agency Branch | Heterociklusos vegyületek rák képalkotására és kezelésére és eljárás ezek alkalamzására |
US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
CA2929345A1 (en) | 2015-09-02 | 2017-03-02 | British Columbia Cancer Agency Branch | Co-targeting androgen receptor splice variants and mtor signaling pathway for the treatment of castration-resistant prostate cancer |
US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
WO2017210771A1 (en) | 2016-06-06 | 2017-12-14 | British Columbia Cancer Agency Branch | Compounds and compositions for radiation therapy and methods of using the same |
KR102397890B1 (ko) | 2016-06-22 | 2022-05-12 | 일립시스 파마 리미티드 | Ar+ 유방암 치료 방법 |
WO2018157232A1 (en) | 2017-02-28 | 2018-09-07 | British Columbia Cancer Agency Branch | Pharmaceutical compositions 'and combinations comprising inhibitors of the androgen receptor a1wd uses thereof |
WO2019023651A2 (en) | 2017-07-28 | 2019-01-31 | Massachusetts Institute Of Technology | MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR |
US11485713B2 (en) | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
PE20211543A1 (es) | 2018-10-18 | 2021-08-16 | Essa Pharma Inc | Moduladores del receptor de androgenos y metodos para su uso |
JP2022510410A (ja) | 2018-12-07 | 2022-01-26 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | 去勢抵抗性および去勢感受性前立腺がんを処置するための方法 |
WO2020198712A1 (en) | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
CN114502539A (zh) | 2019-03-28 | 2022-05-13 | 埃萨制药股份有限公司 | 包含雄激素受体的抑制剂的药物组合物和组合及其用途 |
CN114269331A (zh) | 2019-03-28 | 2022-04-01 | 埃萨制药股份有限公司 | 雄激素受体调节剂和用作蛋白水解靶向嵌合体配体的方法 |
JP2023522040A (ja) | 2020-04-17 | 2023-05-26 | エッサ ファーマ,インコーポレイテッド | N末端ドメインアンドロゲン受容体阻害剤の固体形態およびその使用 |
EP4214183A1 (en) | 2020-09-16 | 2023-07-26 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
-
2017
- 2017-04-17 US US15/489,162 patent/US20170298033A1/en not_active Abandoned
- 2017-04-18 KR KR1020187033112A patent/KR102409651B1/ko active IP Right Grant
- 2017-04-18 NZ NZ748200A patent/NZ748200A/en unknown
- 2017-04-18 AU AU2017250025A patent/AU2017250025B2/en active Active
- 2017-04-18 BR BR112018071183-7A patent/BR112018071183B1/pt active IP Right Grant
- 2017-04-18 JP JP2018554381A patent/JP7142577B2/ja active Active
- 2017-04-18 CA CA3021008A patent/CA3021008A1/en active Pending
- 2017-04-18 EP EP17781660.0A patent/EP3442942B1/en active Active
- 2017-04-18 CN CN201780034942.3A patent/CN109311807B/zh active Active
- 2017-04-18 WO PCT/CA2017/000083 patent/WO2017177307A1/en active Application Filing
- 2017-04-18 ES ES17781660T patent/ES2969445T3/es active Active
- 2017-04-18 MX MX2018012619A patent/MX2018012619A/es unknown
- 2017-04-18 RU RU2018140071A patent/RU2767257C2/ru active
-
2018
- 2018-10-14 IL IL262338A patent/IL262338B/en unknown
-
2020
- 2020-04-14 US US16/848,061 patent/US11142508B2/en active Active
-
2021
- 2021-08-17 US US17/404,589 patent/US11919874B2/en active Active
-
2022
- 2022-06-07 JP JP2022092370A patent/JP2022120018A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102409651B1 (ko) | 2022-06-16 |
RU2018140071A (ru) | 2020-05-19 |
RU2767257C2 (ru) | 2022-03-17 |
CN109311807B (zh) | 2024-08-13 |
IL262338B (en) | 2022-01-01 |
US20210387957A1 (en) | 2021-12-16 |
AU2017250025A1 (en) | 2018-11-29 |
US20170298033A1 (en) | 2017-10-19 |
NZ748200A (en) | 2023-05-26 |
WO2017177307A1 (en) | 2017-10-19 |
EP3442942A4 (en) | 2019-12-04 |
ES2969445T3 (es) | 2024-05-20 |
JP2019513795A (ja) | 2019-05-30 |
AU2017250025B2 (en) | 2021-06-24 |
US11919874B2 (en) | 2024-03-05 |
RU2018140071A3 (es) | 2020-06-01 |
EP3442942B1 (en) | 2023-11-15 |
KR20190011240A (ko) | 2019-02-01 |
EP3442942C0 (en) | 2023-11-15 |
BR112018071183B1 (pt) | 2022-06-07 |
IL262338A (en) | 2018-11-29 |
US20200317628A1 (en) | 2020-10-08 |
EP3442942A1 (en) | 2019-02-20 |
CN109311807A (zh) | 2019-02-05 |
US11142508B2 (en) | 2021-10-12 |
JP7142577B2 (ja) | 2022-09-27 |
JP2022120018A (ja) | 2022-08-17 |
CA3021008A1 (en) | 2017-10-19 |
BR112018071183A2 (pt) | 2019-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ748200A (en) | Bisphenol derivatives and their use as androgen receptor activity modulators | |
NZ733343A (en) | Heterocyclic compounds for cancer imaging and treatment and methods for their use | |
MX2023010043A (es) | Moduladores del receptor de androgenos y metodos para su uso. | |
TN2019000079A1 (en) | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | |
TN2017000243A1 (en) | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
PH12017501816A1 (en) | Azabensimidazoles and their use as amp a receptor modulators | |
MX2016008845A (es) | Derivados de pirrolidinilsulfona y su uso como moduladores del receptor huerfano relacionado con retinoide gamma (ror gamma). | |
PH12019501074A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
NZ704863A (en) | Bicyclic pyridinones useful as gamma secretase modulators | |
AU2019257509A1 (en) | Androgen receptor modulators and methods for their use | |
MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
PH12018502378A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
MX2018004664A (es) | Antagonistas de ep4. | |
TW201613909A (en) | Benzoxazinone amides as mineralocorticoid receptor modulators | |
MY186475A (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
MY192333A (en) | Fused bicylic pyridine compounds and their use as ampa receptor modulators | |
PH12016501645A1 (en) | Aminopyrazolone derivative | |
MX369806B (es) | Compuestos de indolona y su uso como moduladores del receptor ampa. | |
MX2015015290A (es) | Compuestos furanona como inhibidores de quinasa. |